Posted by Michael Wonder on 24 Jun 2021
Evrysdi approved in Japan for the treatment of spinal muscular atrophy
23 June 2021 - 48th country that approved Evrysdi.
PTC Therapeutics today announced that Evrysdi (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labor and Welfare for the treatment of spinal muscular atrophy (SMA).
The approval has been granted based on data from two pivotal studies evaluating Evrysdi in infants and adults living with type 1, 2 or 3 SMA.
